NEW YORK, May 15, 2011 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens, announced today that the Biomedical Advanced Research and Development Authority (BARDA) of the United States Department of Health and Human Services (HHS) has informed SIGA that Chimerix, Inc. has filed a post-award protest against BARDA with respect to the Government’s contract with SIGA to deliver smallpox antiviral ST-246® to the Strategic National Stockpile. Work under the contract will be suspended until further notice pursuant to the applicable protest rules. SIGA’s previous HHS contracts for advanced development of ST-246® for therapeutic use, intravenous formulation of the drug and post-exposure prophylaxis are unaffected by the protest, as is SIGA’s work on commercial-scale validation of the oral adult formulation.
